Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery

Journal of Microencapsulation

Volumn 28, Issue 1, 2011, Pages 37-45

  Ahuja, Munish ^a   Dhake, Avinash S ^b   Sharma, Surendera K ^a   Majumdar, Dipak K ^c  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^b SMBT College of Pharmacy   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Anti inflammatory; Diclofenac; Eudragit S100; Nanosuspension; Ocular

Indexed keywords

DICLOFENAC; EUDRAGIT; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFUSION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG STABILITY; EXPERIMENTAL RABBIT; EYE INFLAMMATION; LEUKOCYTE MIGRATION; NANOPHARMACEUTICS; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; POLYMORPHONUCLEAR CELL; PRECIPITATION; PROSTAGLANDIN SYNTHESIS INHIBITION; SCORING SYSTEM; SUSPENSION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL MOVEMENT; CHEMICAL PRECIPITATION; DICLOFENAC; EYE; FEMALE; INFLAMMATION; MALE; NANOSTRUCTURES; NANOTECHNOLOGY; NEUTROPHILS; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; RABBITS; X-RAY DIFFRACTION;

EID: 78650445731     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.523794     Document Type: Article

References (30)

1. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspen-sions for ophthalmic application. Nanomedicine, 2009;5:90-5.
2. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Effect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugakku Zasshi, 2006;126:1369-75.
3. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J, 2008;10:229-41.
4. Araujo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine, 2009;5:394-401.
5. Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticles formulation using human cornea construct. Int J Pharm, 2008;355:307-13.
6. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: Characterization. Eur J Pharm Biopharm, 2007;67:48-57.
7. Beck RCR, Pohlmann AR, Benvenutti EV, Costa DT, Guterres SS. Nanostructure-coated diclofenac-loaded microparticles: Preparation, morphological characterization, in vitro release and in vivo gastrointestinal tolerance. J Braz Chem Soc, 2005;16:1233-40.
8. Beckett AH, Stenlake JB. 1997. Practical pharmaceutical chemistry. Part 2: Physical methods of analysis. 4th ed. New Delhi: CBS Publishers, pp. 45-51.
9. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemul-sions as ocular drug carriers. J Pharm Sci, 1996;85:530-6.
10. Costa P, Loba JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 2001;13:123-33.
11. Fessi HC, Devissaguet JP, Puisiex F, Thies C. 1992. Inventors, Centre National de la Recherche Scientifique, Paris, assignee. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US patent No. 5 118 528.
12. Garcia-Cabanes C, Palmero M, Bellot JL, Orts A. PGE2 synthesis by corneal endothelial cells: Effect of glucocorticoids and NSAIDs. Ophthalmic Res, 1999;31:42-6.
13. Gordon VJ, Araullo-Cruz T, Romanwoski EG. The effects of topical non-steroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol, 1998;116:900-5.
14. Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: Preparation, characterization and ocular anti-inflammatory studies. Int J Pharm, 2000;209:1-14.
15. Malhotra M, Majumdar DK. Permeation through cornea. Indian J Exp Biol, 2001;39:11-24.
16. Malhotra M, Majumdar DK. Aqueous, oil and ointment formulations of ketorolac: Efficacy against prostaglandinE2-induced ocular inflammation and safety: A technical note. AAPS PharmSciTech, 2006;7:E1-6.
17. Martin AN. 1993. Physical pharmacy: Physical chemical principles in the pharmaceutical sciences. 4th ed. Philadelphia: Lippincott Williams and Wilkins.
18. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47 (2-3):165-96.
19. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 2004;56:827-40.
20. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibu-profen. Eur J Pharm Sci, 2002a;16:53-61.
21. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen - loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002b;23:3247-55.
22. Raizman M. Corticosteroid therapy of eye diseases; fifty years later. Arch Ophthalmol, 1996;114:1000-1.
23. Romanwoski EG, Gordon YJ. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model. Invest Ophthalmol Visual Sci, 2001;42:158-62.
24. Schaffazick SR, Pohlmann AR, Dalla-costa D, Guterres SS. Freeze-drying polymeric colloidal suspensions: Nanocapsules, nanospheres and nanodispersion: A comparative study. Eur J Pharm Biopharm, 2003;56:501-5.
25. Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica, 2003;217:89-98.
26. Schoenwald RD. 1985. Controlled drug bioavailability. In: Smolen VF, Bull L, eds. Bioavailability control by drug delivery system design. Vol. 3, New York: John Wiley & Sons, pp. 257-306.
27. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev, 2001;48:139-57.
28. Sood R. 1999. Medical laboratory technology: Methods and interpretations. 4th ed. New Delhi: Jaypee Brothers, pp. 169-237.
29. Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Visual Sci, 1980;19:1087-93.
30. Sweetman CS. 2005. Martindale: The complete drug reference. 34th ed. London: Pharmaceutical Press.